Dr. Heather Wakelee: How Should We Use Molecular Marker Information for Management of Earlier Stage Non-Small Cell Lung Cancer?

Article

Dr. Heather Wakelee from Stanford University discusses the open question of whether patients with resectable or locally advanced NSCLC should have testing for molecular markers, as well as how we might use this information in clinical practice.

 [powerpress]

Webinar on Refining Prognosis of Early Stage Lung Cancer by Molecular Features, with Dr. Johannes Kratz

Article

The next live webinar to be done through the partnership of GRACE and LUNGevity Foundation will be on the timely subject of using molecular features of a resected non-small cell lung cancer in order to better understand the probability of the cancer recurring. This will be on November 14th, 7 PM Eastern/4 PM Pacific, and will hope to answer the question, "Could these molecular features improve upon current staging efforts to help us refine our recommendations of which patients should receive post-operative chemotherapy in order to reduce the chance of recurrence?"

Top 5 Notable Abstracts in the Small Cell Lung Cancer and Stage I-III NSCLC Track

Article

Here are the 5 presentations at ASCO in stage I-III NSCLC and small cell lung cancer that I think are most interesting and relevant.  You'll note that several are "negative" trials -- blockbusters are hard to come by here -- but even trials that tell us what not to do are important.   And there are some hints of new approaches that could improve outcomes for patients.

1) Prognostic and predictive effects of KRAS mutation subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study. Abstract # 7007

Case Discussion on Adjuvant Therapy for Stage IB NSCLC with Dr. Nasser Hanna

Article

It's been a few months since I sat down with my friend, Dr. Nasser Hanna, a great lung cancer expert from Indiana University, and also a friend in the field. Those of you who have been following GRACE content for a while may have come across his name: he's led a few of the more important trials that are part of our current core knowledge in lung cancer now, such as the